Circulating matrix metalloproteinases in infective endocarditis: A possible marker of the embolic risk

PLoS ONE

Volumn 6, Issue 4, 2011, Pages

  Thuny, Franck ^a,b   Habib, Gilbert ^a   Le Dolley, Yvan ^a   Canault, Matthias ^a,c   Casalta, Jean Paul ^b   Verdier, Monique ^a   Avierinos, Jean François ^a   Raoult, Didier ^b   Mege, Jean Louis ^b   Morange, Pierre Emmanuel ^a,c   Alessi, Marie Christine ^a,c  

^a TIMONE HOSPITAL   (France)

^b AIX MARSEILLE UNIVERSITÉ   (France)

^c INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; GELATINASE B; TISSUE INHIBITOR OF METALLOPROTEINASE; ANTIINFECTIVE AGENT; MATRIX METALLOPROTEINASE;

ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL ENDOCARDITIS; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; EMBOLISM; ENZYME ACTIVITY; FEMALE; HUMAN; MALE; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; RISK ASSESSMENT; VALVULAR HEART DISEASE; ZYMOGRAPHY; BLOOD; CASE CONTROL STUDY; ENZYMOLOGY; MIDDLE AGED; PROSPECTIVE STUDY; RISK FACTOR;

ADULT; AGED; ANTI-BACTERIAL AGENTS; CASE-CONTROL STUDIES; EMBOLISM; FEMALE; HUMANS; MALE; MATRIX METALLOPROTEINASES; MIDDLE AGED; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 79955070367     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0018830     Document Type: Article

References (35)

1. Widmer E, Que YA, Entenza JM, Moreillon P, (2006) New concepts in the pathophysiology of infective endocarditis. Curr Infect Dis Rep 8: 271-279.
2. Moreillon P, Que YA, (2004) Infective endocarditis. Lancet 363: 139-149.
3. Benoit M, Thuny F, Le Priol Y, Lepidi H, Bastonero S, et al. The transcriptional programme of human heart valves reveals the natural history of infective endocarditis. PLoS One 5: e8939.
4. Di Salvo G, Habib G, Pergola V, Avierinos JF, Philip E, et al. (2001) Echocardiography predicts embolic events in infective endocarditis. J Am Coll Cardiol 37: 1069-1076.
5. Vilacosta I, Graupner C, San Roman JA, Sarria C, Ronderos R, et al. (2002) Risk of embolization after institution of antibiotic therapy for infective endocarditis. J Am Coll Cardiol 39: 1489-1495.
6. Thuny F, Di Salvo G, Belliard O, Avierinos JF, Pergola V, et al. (2005) Risk of embolism and death in infective endocarditis: prognostic value of echocardiography: a prospective multicenter study. Circulation 112: 69-75.
7. Snygg-Martin U, Gustafsson L, Rosengren L, Alsiö A, Ackerholm P, et al. (2008) Cerebrovascular complications in patients with left-sided infective endocarditis are common: a prospective study using magnetic resonance imaging and neurochemical brain damage markers. Clin Infect Dis 47: 23-30.
8. Cooper HA, Thompson EC, Laureno R, Fuisz A, Mark AS, et al. (2009) Subclinical brain embolization in left-sided infective endocarditis: results from the evaluation by MRI of the brains of patients with left-sided intracardiac solid masses (EMBOLISM) pilot study. Circulation 120: 585-591.
9. Hetzer R, Hummell M, (2001) Thromboembolism and endocarditis-it's not simply the vegetation. Eur Heart J 22: 811-812.
10. Elkington PT, O'Kane CM, Friedland JS, (2005) The paradox of matrix metalloproteinases in infectious disease. Clin Exp Immunol 142: 12-20.
11. Clark IM, Swingler TE, Sampieri CL, Edwards DR, (2008) The regulation of matrix metalloproteinases and their inhibitors. Int J Biochem Cell Biol 40: 1362-1378.
12. Li JS, Sexton DJ, Mick N, Nettles R, Fowler VG Jr, et al. (2000) Proposed modifications to the Duke criteria for the diagnosis of infective endocarditis. Clin Infect Dis 30: 633-638.
13. Charlson ME, Pompei P, Ales KL, MacKenzie CR, (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40: 373-383.
14. Daniel WG, Mugge A, Martin RP, Lindert O, Hausmann D, et al. (1991) Improvement in the diagnosis of abscesses associated with endocarditis by transesophageal echocardiography. N Engl J Med 324: 795-800.
15. Thuny F, Avierinos JF, Tribouilloy C, Giorgi R, Casalta JP, et al. (2007) Impact of cerebrovascular complications on mortality and neurologic outcome during infective endocarditis: a prospective multicentre study. Eur Heart J.
16. Steckelberg JM, Murphy JG, Ballard D, Bailey K, Tajik AJ, et al. (1991) Emboli in infective endocarditis: the prognostic value of echocardiography. Ann Intern Med 114: 635-640.
17. Baddour LM, Wilson WR, Bayer AS, Fowler VG Jr, Bolger AF, et al. (2005) Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America. Circulation 111: e394-434.
18. Bonow RO, Carabello BA, Chatterjee K, de Leon AC Jr, Faxon DP, et al. (2008) 2008 focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1998 guidelines for the management of patients with valvular heart disease). Endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol 52: e1-142.
19. Habib G, Hoen B, Tornos P, Thuny F, Prendergast B, et al. (2009) Guidelines on the prevention, diagnosis, and treatment of infective endocarditis (new version 2009): The Task Force on the Prevention, Diagnosis, and Treatment of Infective Endocarditis of the European Society of Cardiology (ESC): endorsed by the European Society of Clinical Microbiology and Infectious Diseaes (ESCMID) and the International Society of Chemotherapy (ISC) for Infection and Cancer. Eur Heart J.
20. Dickerman SA, Abrutyn E, Barsic B, Bouza E, Cecchi E, et al. (2007) The relationship between the initiation of antimicrobial therapy and the incidence of stroke in infective endocarditis: an analysis from the ICE Prospective Cohort Study (ICE-PCS). Am Heart J 154: 1086-1094.
21. Kupferwasser LI, Hafner G, Mohr-Kahaly S, Erbel R, Meyer J, et al. (1999) The presence of infection-related antiphospholipid antibodies in infective endocarditis determines a major risk factor for embolic events. J Am Coll Cardiol 33: 1365-1371.
22. Korkmaz S, Ileri M, Hisar I, Yetkin E, Kosar F, (2001) Increased levels of soluble adhesion molecules, E-selectin and P-selectin, in patients with infective endocarditis and embolic events. Eur Heart J 22: 874-878.
23. Ileri M, Alper A, Senen K, Durmaz T, Atak R, et al. (2003) Effect of infective endocarditis on blood coagulation and platelet activation and comparison of patients with to those without embolic events. Am J Cardiol 91: 689-692.
24. Soini Y, Satta J, Maatta M, Autio-Harmainen H, (2001) Expression of MMP2, MMP9, MT1-MMP, TIMP1, and TIMP2 mRNA in valvular lesions of the heart. J Pathol 194: 225-231.
25. Schoen FJ, (2008) Evolving concepts of cardiac valve dynamics: the continuum of development, functional structure, pathobiology, and tissue engineering. Circulation 118: 1864-1880.
26. Yoshinaga M, Niwa K, Niwa A, Ishiwada N, Takahashi H, et al. (2008) Risk factors for in-hospital mortality during infective endocarditis in patients with congenital heart disease. Am J Cardiol 101: 114-118.
27. Rabkin E, Aikawa M, Stone JR, Fukumoto Y, Libby P, et al. (2001) Activated interstitial myofibroblasts express catabolic enzymes and mediate matrix remodeling in myxomatous heart valves. Circulation 104: 2525-2532.
28. Loftus IM, Naylor AR, Bell PR, Thompson MM, (2001) Plasma MMP-9- a marker of carotid plaque instability. Eur J Vasc Endovasc Surg 21: 17-21.
29. Carrell TW, Burnand KG, Wells GM, Clements JM, Smith A, (2002) Stromelysin-1 (matrix metalloproteinase-3) and tissue inhibitor of metalloproteinase-3 are overexpressed in the wall of abdominal aortic aneurysms. Circulation 105: 477-482.
30. Singer CF, Kronsteiner N, Marton E, Kubista M, Cullen KJ, et al. (2002) MMP-2 and MMP-9 expression in breast cancer-derived human fibroblasts is differentially regulated by stromal-epithelial interactions. Breast Cancer Res Treat 72: 69-77.
31. Spinale FG, (2002) Matrix metalloproteinases: regulation and dysregulation in the failing heart. Circ Res 90: 520-530.
32. Vu TH, Werb Z, (2000) Matrix metalloproteinases: effectors of development and normal physiology. Genes Dev 14: 2123-2133.
33. Stamenkovic I, (2003) Extracellular matrix remodelling: the role of matrix metalloproteinases. J Pathol 200: 448-464.
34. Lorente L, Martin MM, Labarta L, Diaz C, Sole-Violan J, et al. (2009) Matrix metalloproteinase-9,-10, and tissue inhibitor of matrix metalloproteinases-1 blood levels as biomarkers of severity and mortality in sepsis. Crit Care 13: R158.
35. Orlandi A, Ciucci A, Ferlosio A, Pellegrino A, Chiariello L, et al. (2005) Increased expression and activity of matrix metalloproteinases characterize embolic cardiac myxomas. Am J Pathol 166: 1619-1628.